![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis Grabs Breakthrough Therapy Designation for Lung Cancer Drug
Novartis Grabs Breakthrough Therapy Designation for Lung Cancer Drug
September 13, 2019
Novartis was granted a breakthrough therapy designation for Capmatinib (INC280) as a first-line treatment for MET-mutated non-small cell lung cancer (NSCLC).
The designation was granted based on the results of a phase 2 clinical trial that showed that the overall response among patients receiving capmatinib was 68 percent for newly treated patients, and 41 percent for previously treated patients.
Incyte granted Novartis worldwide development and commercialization rights to the investigational drug in 2009. Currently, there are no targeted therapies approved to treat the aggressive form of cancer.
Upcoming Events
-
21Oct